Gemcitabine Plus S-1 May Be Safe, Effective for Biliary Tract Cancer

Share this content:
Gemcitabine and S-1 combination chemotherapy may be an alternative therapeutic strategy in metastatic biliary tract cancer.
Gemcitabine and S-1 combination chemotherapy may be an alternative therapeutic strategy in metastatic biliary tract cancer.

Gemcitabine and S-1 combination chemotherapy may be an alternative therapeutic strategy in patients with metastatic biliary tract cancer, a study published in the journal Cancer Chemotherapy and Pharmacology has shown.

For the phase II study, researchers sought to evaluate the safety and efficacy of gemcitabine and S-1, an oral chemotherapy agent related to fluorouracil, combination therapy in patients with metastatic biliary tract cancer.

Researchers enrolled 83 patients between 2005 and 2010. All patients received gemcitabine 1,000mg/m2 IV over 30 minutes on days 1 and 8 plus S-1 80mg/m2 orally on days 1-14 of each 21-day cycle.

Results showed that the overall response rate was 20.6% (95% CI: 8.5-36.7) in the per-protocol population and 18.4% (95% CI: 6.1-30.7) in the intention-to-treat population. The median duration of response was 10.8 months.

RELATED: Second-Line mFOLFOX3 Has Modest Effect in Previously Treated Biliary Tract Cancer

Researchers found that the median progression-free survival was 4.4 months (95% CI: 60.6-87.6) and the median overall survival was 9.0 months (95% CI: 4.0-13.9) in the intention-to-treat population. The 1-year survival rate was 44.7% (95% CI: 29.0-61.5).

In regard to safety, the most common grade 3/4 non-hematologic toxicities were hepatotoxicity, anorexia, and renal toxicity. Neutropenia and anemia occurred in 37.1% and 25.7% of patients, respectively.

Reference

  1. Kim HS, Kim HY, Zang DY, et al. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. Cancer Chemother Pharmacol. 2015;75(4):711-718.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs